Abstract library

11 results for "Parry".
#1704 Diffusion Weighted Imaging as a Screening Tool in the Detection and Monitoring of Pancreatic Neuroendocrine Tumours in Patients with Familial Cancer Syndromes.
Introduction: Pancreatic neuroendocrine tumours (PNETs) occur at a higher frequency and at a younger age in patients with certain genetic conditions e.g. Von Hippel Lindau and Multiple Endocrine Neoplasia type 1. Screening for early detection and monitoring growth rates of PNETs in these high risk patients is vital in their management. MRI has emerged as the gold standard for imaging the pancreas for the detection of PNETs and diffusion weighted imaging (DWI) has become an invaluable adjunct.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Carys Jenkins
Authors: Jenkins C, Thomas W, Parry C, Khan M, ...
Keywords: PNET, MRI, VHL, MEN1
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#37 Gastric GIST with synchronous neuroendocrine tumor of the pancreas, Case Report and Literature Review
Introduction: The Gastrointestinal Stromal Tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. These are rare tumors with an incidence of 15 new cases per million per year. They often occur in individuals over the age of 40 years, without gender predominance. The clinical behavior is variable and benign tumors are the most common. They can develop anywhere in the GI tract, but are more frequent in the stomach and small intestine. The primary treatment, when located, is the surgical resection, which can be complemented with the use of imatinib.
The occurrence of neuroendocrine tumors of the pancreas is rare, representing 1-5% of pancreatic cancers, and it is estimated that its incidence does not exceed 5 to one million. The tumors considered nonfunctioning (15-32% of pancreatic neuroendocrine tumors) are not associated with any syndrome, and are usually incidental. They have a slight predominance in males, and are more frequent in the 6th decade of life. Nonfunctioning tumors of islet cells are virtually all malignant tumors, and the treatment consists of surgical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dra Amelia B Tavares
#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD INES DE TORRES
#384 A Pilot Study on the Immunohistochemical Expression of Chromogranin and/or Synaptophysin in Moderate to Poorly Differentiated Gastroenteropancreatic Carcinomas
Introduction: Recent advances in specific treatment for neuroendocrine tumors (NETs) prompted us to reinvestigate the old phenomenon of neuroendocrine differentiation in carcinomas of the GI tract which has previously been shown to carry no prognostic significance.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr tony W Shek
Authors: Shek T W, Lam W Y, Yao H, Tang V, ...
Keywords: NET, IHC
#802 Metastatic Type 1 Gastric Carcinoid - A Real Threat or Just a Myth?
Introduction: Metastatic GCA1 are extremely rare and there is no data about their natural history, treatment and prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Dr. Simona Glasberg
#1144 Aggressive Multi-Modality Treatment of Pancreatic Neuroendocrine Tumors (pNETs): Outcomes in Patients with Advanced Disease
Introduction: pNETs carry the worst prognosis of all NETs, particularly when hepatic metastasis are present. We try to actively treat all patients referred.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Damian Mayo
Authors: Mayo D, Armstrong T, Cave J, Nolan L, ...
#1150 Platelet Serotonin But Not Dopamine Concentrations Are Lower in Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Patients Compared to Healthy Individuals.
Introduction: Platelets carry VEGF-A, serotonin and dopamine. Serotonin stimulates and dopamine inhibits tumor angiogenesis. We hypothesized that platelets are activated in tumor vasculature and release angiogenic factors, resulting in lower platelet serotonin and dopamine.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Marloes Peters
#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
#1415 Detection of SSTR2 and 5 Expression on Circulating Tumour Cells in Neuroendocrine Tumours
Introduction: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR) which can be targeted for therapy with somatostatin analogues (SSA) or radionuclide treatment.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: DR Alexa Childs
Authors: Childs A, Vesely C, Ensell L, Luong T, ...
Keywords: CTC, SSTR